Gain Therapeutics Announces Poster Presentation at AD/PD 2025
Gain Therapeutics (NASDAQ: GANX) has announced its upcoming poster presentation at the AD/PD™ 2025 International Conference in Vienna, Austria, scheduled for April 1-5, 2025. The presentation will detail the design of their Phase 1b clinical trial for GT-02287 in Parkinson's disease.
The poster (Number: SHIFT 02-072), titled 'Design of a Phase 1b Study to Evaluate the GCase-Targeting Molecule GT-02287 in GBA1-PD and Sporadic PD,' will be presented by Raffaella Pozzi, Vice President of Clinical Operations at Gain Therapeutics.
Gain Therapeutics (NASDAQ: GANX) ha annunciato la sua prossima presentazione di poster alla AD/PD™ 2025 International Conference a Vienna, Austria, programmata per il 1-5 aprile 2025. La presentazione fornirà dettagli sul design del loro studio clinico di Fase 1b per GT-02287 nella malattia di Parkinson.
Il poster (Numero: SHIFT 02-072), intitolato 'Design di uno studio di Fase 1b per valutare la molecola mirata GCase GT-02287 in GBA1-PD e PD sporadico,' sarà presentato da Raffaella Pozzi, Vicepresidente delle Operazioni Cliniche di Gain Therapeutics.
Gain Therapeutics (NASDAQ: GANX) ha anunciado su próxima presentación de póster en la AD/PD™ 2025 International Conference en Viena, Austria, programada para el 1-5 de abril de 2025. La presentación detallará el diseño de su ensayo clínico de Fase 1b para GT-02287 en la enfermedad de Parkinson.
El póster (Número: SHIFT 02-072), titulado 'Diseño de un estudio de Fase 1b para evaluar la molécula dirigida GCase GT-02287 en GBA1-PD y PD esporádico,' será presentado por Raffaella Pozzi, Vicepresidenta de Operaciones Clínicas en Gain Therapeutics.
Gain Therapeutics (NASDAQ: GANX)는 오스트리아 비엔나에서 2025년 4월 1일부터 5일까지 예정된 AD/PD™ 2025 국제 회의에서 포스터 발표를 할 것이라고 발표했습니다. 이 발표에서는 파킨슨병에 대한 GT-02287의 1b상 임상 시험 설계에 대한 세부사항이 포함될 것입니다.
포스터(번호: SHIFT 02-072), 제목은 'GBA1-PD 및 우발적 PD에서 GCase 표적 분자 GT-02287을 평가하기 위한 1b상 연구 설계'로, Gain Therapeutics의 임상 운영 부사장인 Raffaella Pozzi가 발표할 예정입니다.
Gain Therapeutics (NASDAQ: GANX) a annoncé sa prochaine présentation de poster lors de la AD/PD™ 2025 International Conference à Vienne, en Autriche, prévue du 1er au 5 avril 2025. La présentation détaillera la conception de leur essai clinique de Phase 1b pour GT-02287 dans la maladie de Parkinson.
Le poster (Numéro : SHIFT 02-072), intitulé 'Conception d'une étude de Phase 1b pour évaluer la molécule ciblant GCase GT-02287 dans le GBA1-PD et le PD sporadique,' sera présenté par Raffaella Pozzi, Vice-Présidente des Opérations Cliniques chez Gain Therapeutics.
Gain Therapeutics (NASDAQ: GANX) hat seine bevorstehende Posterpräsentation auf der AD/PD™ 2025 International Conference in Wien, Österreich, bekannt gegeben, die vom 1. bis 5. April 2025 stattfinden wird. Die Präsentation wird das Design ihrer Phase 1b-Studie für GT-02287 bei Parkinson-Krankheit detailliert darstellen.
Das Poster (Nummer: SHIFT 02-072), mit dem Titel 'Design einer Phase 1b-Studie zur Bewertung des GCase-zielgerichteten Moleküls GT-02287 bei GBA1-PD und sporadischer PD,' wird von Raffaella Pozzi, Vice President für Klinische Operationen bei Gain Therapeutics, präsentiert.
- None.
- None.
BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson’s disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria.
Details of the poster are as follows:
Poster Number: SHIFT 02-072
Poster Title: Design of a Phase 1b Study to Evaluate the GCase-Targeting Molecule GT-02287 in GBA1-PD and Sporadic PD
Presenting Author: Raffaella Pozzi, Vice President of Clinical Operations, Gain Therapeutics
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, and improved motor function and cognitive performance. Additionally, GT-02287 significantly reduced plasma neurofilament light chain (NfL) levels, an emerging biomarker of neurodegeneration.
Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow or stop the progression of Parkinson’s disease.
Gain’s lead program in Parkinson’s disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com
Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
